Document is current
Any future updates will be listed below
-
Authors
Nia, Hadi T.
Liu, Hao
Seano, Giorgio
Datta, Meenal
Jones, Dennis
Rahbari, Nuh
Incio, Joao
Chauhan, Vikash P.
Jung, Keehoon
Martin, John D. http://orcid.org/0000-0002-9828-8203
Askoxylakis, Vasileios
Padera, Timothy P.
Fukumura, Dai
Boucher, Yves
Hornicek, Francis J.
Grodzinsky, Alan J.
Baish, James W.
Munn, Lance L.
Jain, Rakesh K.
- License Information
-
More Information
Article History
Received: 21 April 2016
Accepted: 11 August 2016
First Online: 28 November 2016
Competing interests
: R.K.J. received consultant fees from Ophthotech, SPARC, SynDevRx and XTuit. R.K.J. owns equity in Enlight, Ophthotech, SynDevRx and XTuit, and serves on the Board of Directors of XTuit and the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, the Tekla Healthcare Opportunities Fund and the Tekla World Healthcare Fund. No reagents or funding from these companies were used in these studies.
